S.BIOMEDICS revealed promising one-year post-transplant data from their Phase 1/2a clinical trial of the TED-A9 cell therapy for Parkinson's disease. The data demonstrate efficacy profile of TED-A9 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback